THE TWO-YEAR THERAPY WITH OMALIZUMAB IN CHILDREN WITH SEVERE PERSISTENT UNCONTROLLED ASTHMA- DYNAMICS OF QUALITY OF LIFE
Author(s)
Namazova-Baranova L, Vishneva E, Dobrynina E, Alekseeva A, Levina J, Efendieva K, Antonova E, Smirnov V, Vinyarskaya I, Selimzianova L, Chemakina D, Kalugina V
FSAI “National Scientific and Practical Center of Children’s Health” of the Ministry of Health of the Russian Federation, Moscow, Russia, Moscow, Russia
OBJECTIVES: Omalizumab is one of the most frequently used recombinant, humanized, monoclonal antibody treatment in children with bronchial asthma (BA). Dynamics of quality of life (QoL) is the important aspect to assess the response to treatment in children with uncontrolled severe persistent BA. To determine the cut-off of the significant quality of life improvement in the first 2 years of therapy with Omalizumab, according to the pediatric patient registry with severe persistent uncontrolled BA METHODS: Data of 34 children (average age 12,2 years) with severe uncontrolled persistent BA, who got the treatment with Omalizumab from January 2015 to June 2017, were analyzed. The quality of life of all children was assessed with the questionnaire PAQLQ(S): before the therapy with Omalizumab, in 16 weeks, in 6 months, in 9 months and then every 6 months. The maximum treatment time period for Omalizumab was 2 years. RESULTS: Positive dynamics of QoL was observed in all children. After 16 weeks of therapy the total score of QoL (TsQoL) was improved by 18% (p=0,000); after 6 months - by 23.82% (p=0,000); after 9 months – by 25,44% (p=0.000); after 1 year – by 26,42% (p=0,000); after 1,5 year – by 25,92% (p=0,000); after 2 years – 27,54% (p=0,000). All children had a positive dynamics of BA during the therapy with Omalizumab: the number of exacerbations and the requirement of quick-relief medications have been reduced, asthma control has been improved; there was no severe exacerbation requiring emergency admissions; the basic therapy volume was reduced by half after 6 months of the therapy with Omalizumab in 2 children. CONCLUSIONS: Our results indicate that the minimum duration of the treatment with Omalizumab should be at least 1 year in children with severe persistent asthma. Results require further analysis.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PRS54
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
Pediatrics, Respiratory-Related Disorders